Pharming Group N.V. (PHAR) Cash & Equivalents (2019 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Pharming (PHAR) has disclosed Cash & Equivalents for 4 consecutive years, with $207.3 million as the latest value for Q4 2022.

• For the quarter ending Q4 2022, Cash & Equivalents rose 8.03% year-over-year to $207.3 million, compared with a TTM value of $207.3 million through Dec 2022, up 8.03%, and an annual FY2022 reading of $207.3 million, up 8.03% over the prior year.
• Cash & Equivalents was $207.3 million for Q4 2022 at Pharming, up from $191.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $207.3 million in Q4 2022 and bottomed at $74.3 million in Q4 2019.
• Average Cash & Equivalents over 4 years is $168.2 million, with a median of $195.6 million recorded in 2020.
• The sharpest move saw Cash & Equivalents skyrocketed 167.92% in 2020, then dropped 3.65% in 2021.
• Year by year, Cash & Equivalents stood at $74.3 million in 2019, then surged by 167.92% to $199.2 million in 2020, then dropped by 3.65% to $191.9 million in 2021, then increased by 8.03% to $207.3 million in 2022.
• Business Quant data shows Cash & Equivalents for PHAR at $207.3 million in Q4 2022, $191.9 million in Q4 2021, and $199.2 million in Q4 2020.

Peer Comparison